362 related articles for article (PubMed ID: 34516493)
1. Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.
Li L; Zhang Z; Hu Y
Medicine (Baltimore); 2021 Sep; 100(36):e27029. PubMed ID: 34516493
[TBL] [Abstract][Full Text] [Related]
2. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
4. Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis.
Tian Z; Liang C; Zhang Z; Wen H; Feng H; Ma Q; Liu D; Qiang G
World J Surg Oncol; 2020 May; 18(1):116. PubMed ID: 32473655
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
[TBL] [Abstract][Full Text] [Related]
6. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase.
Xiong Q; Huang Z; Xin L; Qin B; Zhao X; Zhang J; Shi W; Yang B; Zhang G; Hu Y
Cancer Immunol Immunother; 2021 Mar; 70(3):713-720. PubMed ID: 32910245
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer.
Yan P; Han Y; Tong A; Liu J; Wang X; Liu C
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34286335
[TBL] [Abstract][Full Text] [Related]
8. High pretreatment plasma D-dimer levels are associated with shorter overall survival in patients with small cell lung cancer.
Fan S; Zhao G; An G
J Int Med Res; 2019 Jan; 47(1):215-224. PubMed ID: 30270808
[TBL] [Abstract][Full Text] [Related]
9. Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Suh KJ; Keam B; Kim M; Park YS; Kim TM; Jeon YK; Kim DW; Chung DH; Kim YW; Heo DS
Clin Lung Cancer; 2016 Jul; 17(4):245-252.e1. PubMed ID: 26719155
[TBL] [Abstract][Full Text] [Related]
10. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
Peng Y; Wang Y; Li J; Hao X; Hu X
Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
[TBL] [Abstract][Full Text] [Related]
11. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract][Full Text] [Related]
12. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.
Fizazi K; Cojean I; Pignon JP; Rixe O; Gatineau M; Hadef S; Arriagada R; Baldeyrou P; Comoy E; Le Chevalier T
Cancer; 1998 Mar; 82(6):1049-55. PubMed ID: 9506348
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
14. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study.
Tong L; Wan Y; Shi X; Liu X; Liu Z; Li Y; Zhang Y; Luo D; Zhu J
Cancer Control; 2024; 31():10732748241253959. PubMed ID: 38736182
[TBL] [Abstract][Full Text] [Related]
18. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
[TBL] [Abstract][Full Text] [Related]
19. Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer.
Zhou M; Wang Z; Yao Y; Zhou H; Liu M; Sun J
Clin Transl Oncol; 2017 Jul; 19(7):865-873. PubMed ID: 28127669
[TBL] [Abstract][Full Text] [Related]
20. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
